Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neotropix names new CMO
In this new role as CMO, Dr Williams will be responsible for patient safety, general medical governance, ethics and integrity, medical information and investigations involving human subjects relating
In this new role as CMO, Dr Williams will be responsible for patient safety, general medical governance, ethics and integrity, medical information and investigations involving human subjects relating
The financing was co-led by Mitsubishi UFJ Capital and Genzyme Ventures, both new investors, with the participation of the company’s previous investors, MPM Capital, Alloy Ventures, GBS Ventures,
The results from this trial are not intended or required for inclusion in Wyeth’s currently planned regulatory filings for the use of the 13-valent pneumococcal conjugate candidate vaccine
Under the terms of this exclusive agreement, Capsugel will be responsible for the formulation and encapsulation of naproxcinod active pharmaceutical ingredient (API), using its patented Lems technology. The
The court has also announced that a trial date will be scheduled and is likely to be in January 2009. AstraZeneca remains focused on preparing for this trial
The effort will apply Arcxis’s proprietary technology for isolation and concentration of total RNA and genomic DNA to PCR and RT-PCR based diagnostic tests. Arcxis believes that its
SCH900105 (AV-299) is being developed in collaboration with Schering-Plough. Under the terms of the agreement, human dosing with SCH900105 (AV-299) triggers a $3 million milestone payment from Schering-Plough
In his new position, Dr Fuller will work closely with Oriel co-founder, president and COO Paul Atkins. Prior to joining Oriel, Dr Fuller has served in a number
Under the terms of the agreement, Impulse Monitoring (IMI) will provide Legacy Emanuel with comprehensive intraoperative neuromonitoring (IONM) services including IMI-qualified neurophysiologists and real-time professional oversight experienced physicians.
In return for the license, Kuros will receive upfronts, milestones and royalties on the sale of Aeris’s lead product, the AeriSeal biologic lung volume reduction (BLVR) system, a